Innovative trial approaches in immune-mediated inflammatory diseases: Current use and future potential

DOI: 10.21203/rs.3.rs-63613/v1

Efficient analysis of time-to-event endpoints when the event involves a continuous variable crossing a threshold

*Journal of Statistical Planning and Inference* 2020; 208:119-29

Controlling type I error rates in multi-arm clinical trials: A case for the false discovery rate

*Pharmaceutical Statistics* 2020

Increasing power in the analysis of responder endpoints in rheumatology: a software tutorial

*medRxiv* 2020

Developing and testing high-efficacy patient subgroups within a clinical trial using risk scores

*Statistics in Medicine* 2020; 39(24):3285-3298

Developing a predictive signature for two trial endpoints using the cross-validated risk scores method

*arXiv* 2020; arXiv:2007.01680

Efficient adaptive designs for clinical trials of interventions for COVID-19

*Statistics in Biopharmaceutical Research* 2020; 12(4):483-497

A review of Bayesian perspectives on sample size derivation for confirmatory trials

*arXiv* 2020; arXiv:2006.15715

Including non-concurrent control patients in the analysis of platform trials: Is it worth it?

*BMC Medical Research Methodology* 2020; 20:165

Graphical approaches for the control of generalised error rates

*Statistics in Medicine* 2020